Table 1 Descriptive characteristics of patients who received physical therapy after knee or hip replacement surgery (2015–2018)
Characteristic | TKA (n = 15,309) | THA (n = 14,325) |
|---|---|---|
 Mean number of post-discharge PT sessions (SD) | 20.70 (11.3) | 16.68 (10.1) |
Predisposing factors | ||
 Female (%) | 63 | 66 |
 Age (SD) | 68.79 (9.3) | 70.07 (10.3) |
 SES (%) | ||
  - Low | 16 | 15 |
  - Below average | 18 | 7 |
  - Average | 25 | 24 |
  - Above average | 27 | 28 |
  - High | 24 | 26 |
Enabling factors patient | ||
 Supplementary insurance (%) | 97 | 98 |
 Mean travel time to hospital in minutes (SD) | 27.30 (20.9) | 27.82 (20.6) |
 Mean travel time to PT in minutes (SD) | 2.48 (4.5) | 2.60 (4.6) |
 Received non-TJA-related PT (%) | 36 | 38 |
  - mean number of non-TJA-related PT sessions between 6 to 12 months prior to surgery (SD) | 10.92 (10.1) | 10.53 (10.1) |
Enabling factors hospital (n = 102) | ||
 Type of hospital % | ||
  - General | 41 | 42 |
  - Specialized | 4 | 3 |
  - Academic | 2 | 2 |
  - Top clinical | 41 | 45 |
  - Independent treatment center | 12 | 7 |
 Mean procedure volume per hospital per year (SD) | 855.62 (465.3) | 873.13 (457.4) |
Enabling factors PT clinic (n = 4347) | ||
 Mean number of all PT sessions claimed by PT clinics per year (SD) | 6781.89 (6783.5) | 6705.19 (6916.8) |
 Contract type PT % | ||
  - Uncontracted | 3 | 3 |
  - Standard | 3 | 3 |
  - Basic | 55 | 56 |
  - Plus | 38 | 37 |
Need factors | ||
 Received TJA-related pre-operative PT % | 46 | 51 |
  - mean number of TJA-related PT sessions in 6 months prior to surgery (SD) | 10.30 (10.6) | 10.23 (10.4) |
 Received pre-operative homecare % | 7 | 9 |
  - mean number of hours of homecare received (SD) | 9.27 (19.7) | 6.53 (11.3) |
 Diabetes % | 19 | 14 |
  - Insulin % | 5 | 3 |
  - Other glucose-lowering drugs % | 14 | 10 |
 COPD % | 17 | 15 |
 Cardiovascular disease % | 67 | 63 |
  - Antihypertensives % | 33 | 28 |
  - Beta-blockers % | 15 | 14 |
  - Cholesterol-lowering agents % | 6 | 6 |
  - Anti-arrhythmia or vasoprotective agents % | 13 | 15 |